10 Adverse events 5% in SUSTAIN 5 8,10 AEs occurring in 5% of participants treated with Ozempic in SUSTAIN 5 Incidence of severe hypoglycemia was 1.5% across all placebo-controlled trials 1 Incidence of severe hypoglycemia or blood glucose-confirmed hypoglycemia (% of patients) was 8,10 : 8.3% with Ozempic 0.5 mg + basal insulin MET 10.7% with Ozempic 1 mg + basal insulin MET 5.3% with placebo + basal insulin MET Patients receiving Ozempic in combination with an insulin secretagogue (eg, sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia 1 ADA=American Diabetes Association
Contraindications Based on mechanism of action and conservative interpretation of potential risks, BPC-157 use is generally discouraged in individuals with active or recent cancer, pregnancy or breastfeeding, autoimmune conditions with active flares, children and adolescents (unknown effects on development), and known hypersensitivity to any peptide compounds
Here is an honest summary of what you can and cannot expect: What You CAN Realistically Expect Measurably softer, smoother skin texture within 34 weeks Visible reduction in fine lines, especially around the eyes, by weeks 48 Significantly firmer, more lifted-feeling skin by weeks 812 Reduced redness and improved skin tone uniformity from early weeks Improved healing of acne scarring, post-procedure recovery, and damaged skin A progressive, compounding improvement that continues building over months Hair thickness improvements with consistent scalp application over 812 weeks What You Should NOT Expect Dramatic wrinkle erasure in 12 weeks (those claims involve misleading photography or film-forming agents) Botox-equivalent muscle relaxation (GHK-Cu doesn't inhibit neurotransmitters that's Argireline/SNAP-8's role) Permanent results without ongoing use like all biological interventions, maintenance is required Identical results to someone else skin type, age, damage severity, and application consistency all affect outcomes GHK-Cu's results are directly proportional to consistency
Gentilella, R., Pechtner, V., Corcos, A
